Generic Name and Formulations:
Nepafenac 0.1%, oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for NEVANAC:
Post-operative pain and inflammation following cataract surgery.
≥10yrs: 1 drop in affected eye(s) 3 times daily starting one day before surgery, continued on day of surgery, and through first 2 weeks post-op.
<10yrs: not established.
Bleeding tendencies. May delay wound healing. Complicated/repeat ocular surgeries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Risk of corneal adverse events may be increased if used more than 24 hours before surgery, or beyond 14 days post-op. Contact lenses (remove during therapy). Pregnancy (Cat.C; avoid during 3rd trimester). Nursing mothers.
Caution with concomitant medications that may prolong bleeding time. Increased potential for healing problems with concomitant topical steroids.
Ocular effects (eg, capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, sticky sensation, edema, dry eye, lid margin crusting, discomfort, hyperemia, pain, pruritus, photophobia, tearing, vitreous detachment), headache, hypertension, GI upset, sinusitis.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|